Replies to post #439613 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

To your point: waiting for the five year data point should help the survival K-M curve for DC Vax in the now secondary endpoint of comparing the DCVax-L crossover arm to recurrent GBM ECAs.

[ATLnsider]

I agree that the 5-year DCVax-L overall survival (OS) data is much more irrefutable and undeniable, than the 3-year DCVax-L OS data.

[flipper44]

We are currently six years and three months since the 331st (last) patient was enrolled. There is something called long term follow up. In such cases, unblinded review is typically continued after TLD comes out. NWBO chose to remain blinded through five years from the last patient’s enrollment. Optune is an exception, they stopped any follow up at two years after last patient was enrolled. These (DCVax-l and Optune) are opposing extremes in this regard.

Optune’s extrapolated (long term) claims would have been significantly hurt by reality if they had continued to follow their patients, IMO, as it was obvious survival was degrading.